Biotechnological company OncoMax, Ltd, which is the first project jointly invested by Maxwell Biotech Venture Fund and RVC Seed Fund, has successfully finished development and preclinical efficacy study of targeted medicine based on humanised monoclonal antibody, which blocks fibroblast growth factor receptor. The study results have already been approved by expert commissions of several largest international conferences in this field and have been voiced in the lecture Mechanisms and Ways to Overcome Resistance to mTOR and VEGFR Inhibitors at the International Scientific Symposium on Achievements in Treatment of Renal Cell Carcinoma, which took place in Yekaterinburg on September 10. In the nearest future they will also be offered in the form of reports at the 11th International Kidney Cancer Symposium (Chicago, October 2011) and at the 4th European Multidisciplinary Meeting on Urological Cancers (Barcelona, November 2011).
OncoMax, Ltd is a Russian innovation company included in Maxwell Biotech Group Biotechnological Holding and Biomedical Cluster of Skolkovo Innovation Center. The main activity of OncoMax is directed at development and bringing innovative biopharmaceutical medicines for diagnostics and treatment of oncological diseases to the Russian market. The first medicinal product of the company, named ОМ-RCA-01, is indicated for targeted therapy of renal cancer and has been granted with numerous Russian and foreign awards.
The results of studies on cell models (in vitro) received in August 2011 demonstrate that humanised monoclonal antibody ОМ-RCA-01 blocks fibroblast growth factor receptor, inhibiting growth of tumour cells of renal cell carcinoma. Studies carried out on animal models (in vivo) also demonstrate tumour growth inhibition when using the medicine. In the course of experiments statistically reliable differences in the tumour volume and survival indices were achieved between test animal groups and control groups. Thus, efficacy of humanised monoclonal antibody ОМ-RCA-01 was proved on cell and animal models, it persistently blocks the specific target at the tumour cell, inhibiting tumour development mechanisms. Further studies should evaluate the toxicity of the received monoclonal antibody in animals, and clinical studies of Phases I and II will evaluate preliminary efficacy and toxicity of humanised antibody in human.